Release characteristics and osteogenic activity of recombinant human bone morphogenetic protein-2 grafted to novel self-assembled poly(lactide-co-glycolide fumarate) nanoparticles.
Functionalized biodegradable nanoparticles (NPs) provide reactive groups and large surface area for grafting recombinant human bone morphogenetic protein-2 (rhBMP-2) to reduce protein diffusion and maintain sufficient concentration for recruitment and differentiation of osteoprogenitor cells. The objective of this work was to investigate release characteristics and osteogenic activity of rhBMP-2, grafted to biodegradable NPs based on succinimide-terminated poly(lactide fumarate) (PLAF-NHS) and poly(lactide-co-glycolide fumarate) (PLGF-NHS) macromers. The release of rhBMP-2 from the NPs, measured by enzyme-linked immunosorbent assay, was linear with time in the first two weeks, and 24.70+/-1.30% and 48.7+/-0.7% of the protein grafted to PLGF-NHS and PLAF-NHS NPs, respectively, was released in the enzymatically active conformation after complete degradation/erosion of the NPs. After 14 days of incubation with bone marrow stromal (BMS) cells, rhBMP-2 grafted to PLAF-NHS and PLGF-NHS NPs was as effective in inducing mineralization as the native rhBMP-2 that was directly added to the cell culture media. At any incubation time, rhBMP-2 grafted to PLAF had the highest expression of osteopontin (OP) and osteocalcin (OC), followed by rhBMP-2 grafted to PLGF and rhBMP-2 directly added to media. Higher OP and OC expression for BMP-gPLAF and BMP-gPLGF groups may be related to other factors in the cascade of osteogenesis, such as differentiation of BMS cells to the vasculogenic lineage and formation of a vascularized/mineralized matrix.
Mercado
Angel E
AE
Biomimetic Materials and Tissue Engineering Laboratory, Department of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA.
Ma
Junyu
J
He
Xuezhong
X
Jabbari
Esmaiel
E
D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism; D055396:Bone Morphogenetic Protein 2 / Q000737:chemistry / Q000494:pharmacology*; D002113:Calcification, Physiologic / Q000187:drug effects; D002478:Cells, Cultured; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D004339:Drug Compounding; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007700:Kinetics; D008297:Male; D053758:Nanoparticles; D015675:Osteocalcin / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects*; D053495:Osteopontin / Q000378:metabolism; D011091:Polyesters / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology; D012995:Solubility; D017154:Stromal Cells / Q000187:drug effects* / Q000378:metabolism
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D004337:Drug Carriers; D011091:Polyesters; D011994:Recombinant Proteins; C506897:Spp1 protein, rat; D015675:Osteocalcin; D053495:Osteopontin
Dent Mater J. 2007 Jul;26(4):487-92
17886451
Biomaterials. 2006 Dec;27(36):6138-49
16895736
J Biochem Biophys Methods. 1999 Jan 13;38(1):17-28
10078870
Biomacromolecules. 2005 Jul-Aug;6(4):2312-9
16004477
Spine (Phila Pa 1976). 2006 Mar 1;31(5):542-7
16508549
Cancer Lett. 2003 Jul 30;198(1):107-17
12893437
Biotechnol Bioeng. 2008 Mar 1;99(4):996-1006
17879301
Tissue Eng. 2001 Aug;7(4):373-83
11506727
Biophys J. 2008 Jun;94(11):4473-83
18326646
Biomaterials. 2008 Mar;29(9):1189-97
18083224
J Biol Chem. 2005 Apr 15;280(15):14974-80
15695507
Surgeon. 2007 Aug;5(4):232-43
17849959
J Immunol. 2003 Jul 15;171(2):1085-93
12847283
J Control Release. 2004 Mar 5;95(2):249-56
14980773
J Chem Phys. 2007 Mar 7;126(9):095101
17362129
J Control Release. 2005 Nov 28;108(2-3):271-81
16169112
Spine (Phila Pa 1976). 2002 Aug 15;27(16 Suppl 1):S2-8
12205411
Biomaterials. 2005 Aug;26(24):5085-92
15769544
Biomaterials. 2006 Mar;27(8):1598-607
16146647
J Control Release. 2007 Aug 16;121(1-2):91-9
17604871
J Control Release. 2005 Aug 18;106(1-2):162-71
15972241
Biochem Biophys Res Commun. 2008 May 2;369(2):774-80
18313401
J Biomed Mater Res A. 2009 Apr;89(1):124-37
18431754
Biomaterials. 2007 Apr;28(12):2087-96
17239946
Biomacromolecules. 2007 Mar;8(3):780-92
17295540
Spine (Phila Pa 1976). 1999 Apr 1;24(7):629-36
10209790
Langmuir. 2008 Nov 4;24(21):12508-16
18837524
Int J Pharm. 2006 May 18;314(2):198-206
16504431
J Mol Biol. 1999 Mar 19;287(1):103-15
10074410
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Int J Pharm. 2008 Jul 9;359(1-2):294-7
18457929
AAPS PharmSciTech. 2001 Oct 07;2(3):E18
14727877
J Craniofac Surg. 2005 Nov;16(6):1006-14
16327548
Macromol Biosci. 2008 Jun 11;8(6):499-507
17941111
J Control Release. 2007 Mar 12;118(1):65-77
17250921
Biomacromolecules. 2007 Feb;8(2):406-15
17253761
Pharm Res. 2008 Jul;25(7):1552-62
18196205
Blood. 1995 May 1;85(9):2414-21
7537113
Acta Biomater. 2008 Sep;4(5):1126-38
18474452
Expert Rev Med Devices. 2008 Jan;5(1):75-84
18095899
Spine (Phila Pa 1976). 2002 Aug 15;27(16 Suppl 1):S66-85
12205423
J Mater Sci Mater Med. 2008 Jan;19(1):311-8
17597374
Nanotechnology. 2008 Aug 13;19(32):325609
21828822